Abstract
Two single arm, Phase II trials (3 and 5) were undertaken to determine the efficacy and toxicity of an adjuvant treatment using Hyper-IL-6 gene-modified whole-cell allogeneic melanoma vaccine in patients with stage IIIB-IV resected disease. Ninety-seven and 99 patients were enrolled into Trials 3 and 5, respectively. The primary endpoint was disease-free survival (DFS), and the secondary was overall survival (OS). Vaccine was administered eight times every 2 weeks (induction), every month (maintenance) until patient's death. At progression, maintenance was continued or induction was repeated followed by maintenance. Median follow-up was 10.5 and 6.2 years for Trials 3 and 5, respectively. No grade 3 or 4 toxicities were observed. An extension of DFS and OS was observed, when compared with historical non-treated controls. DFS probability at 5 years for Trials 3 and 5 was, respectively, 54.8% and 40.6% for stage IIIB, 25.0% and 24.0% for IIIC, and 8.5% and 17.7% for IV. OS probability at 5 years was, respectively, 66.7% and 56.3% for IIIB, 43.8% and 39.8% for IIIC, and 26.1% and 41.2% for IV. Continuous vaccination, regardless of the disease progression, re-induction, and immunization of patients until death resulted in patients ...Continue Reading
References
Oct 15, 1982·Cancer·L G FeunE J Freireich
Jun 1, 1995·Human Gene Therapy·A MackiewiczS Rose-John
Feb 1, 1995·Cytokine·A MackiewiczS Rose-John
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Feb 1, 1997·Nature Biotechnology·M FischerS Rose-John
Jun 1, 1997·Cancer Immunology, Immunotherapy : CII·F BelliC Sanatonio
Dec 28, 1999·Human Gene Therapy·F ArientiC Sanantonio
Feb 3, 2000·Journal of the National Cancer Institute·P TherasseS G Gwyther
Apr 11, 2000·Human Gene Therapy·S OsantoP I Schrier
Sep 21, 2000·Immunology Letters·S NawrockiA Mackiewicz
Jun 25, 2002·Biological Psychiatry·Matthew J HoptmanKelvin O Lim
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HerseyR John Simes
Oct 11, 2003·Fish & Shellfish Immunology·Bertrand ColletChristopher J Secombes
Oct 6, 2004·Expert Opinion on Biological Therapy·Piotr J WysockiA Mackiewicz
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Jan 2, 2007·Journal of Immunotherapy·Axel HoosUNKNOWN Cancer Vaccine Clinical Trial Working Group
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm S MitchellVicky E Jones
Aug 10, 2007·Expert Opinion on Investigational Drugs·Sergiusz Nawrocki, Andrzej Mackiewicz
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Djordje AtanackovicSacha Gnjatic
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward L KornJohn M Kirkwood
Jul 16, 2008·Lancet·Alexander Mm EggermontUNKNOWN EORTC Melanoma Group
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Franz O SmithSteven A Rosenberg
Sep 11, 2008·Melanoma Research·Thomas K EigentlerUNKNOWN German Dermatologic Cooperative Oncology Group
Oct 20, 2009·European Journal of Pharmacology·Jacek Mackiewicz, Andrzej Mackiewicz
Nov 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander M M Eggermont
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Feb 20, 2010·Cancer Gene Therapy·P J WysockiA Mackiewicz
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 26, 2010·Transplantation Proceedings·J Mackiewicz, A Mackiewicz
Nov 16, 2010·Seminars in Oncology·Alexander M M EggermontCaroline Robert
Jan 8, 2011·The Oncologist·Claus GarbeJohn M Kirkwood
Jun 3, 2011·The New England Journal of Medicine·Douglas J SchwartzentruberPatrick Hwu
Sep 29, 2011·The Cancer Journal·Giorgio ParmianiVincenzo Russo
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Mar 29, 2012·The Cancer Journal·Anna M LeungDonald L Morton
Mar 29, 2012·The Cancer Journal·Diwakar DavarJohn M Kirkwood
Citations
Jul 24, 2014·Future Oncology·Miles C AndrewsAndreas Behren
Dec 12, 2012·Expert Opinion on Investigational Drugs·Malgorzata Mackiewicz-WysockaPiotr J Wysocki
Feb 20, 2016·Cancer Immunology, Immunotherapy : CII·Julia M GreeneGeorge E Peoples
Aug 12, 2015·Gene Therapy·M-C ChangW-F Cheng
May 29, 2015·Medicine·Jacek MackiewiczAndrzej Mackiewicz
Apr 10, 2013·Gene·Anna KozłowskaAndrzej Mackiewicz
Jun 15, 2016·Stem Cells·Alessandra TuccittoMichela Perego
Sep 11, 2018·Anti-cancer Agents in Medicinal Chemistry·Izabela ŁasińskaJacek Mackiewicz
May 3, 2014·Current Treatment Options in Oncology·Sarah A WeissAnna C Pavlick
Apr 1, 2020·Vaccines·Agnieszka Gąbka-BuszekAndrzej Mackiewicz
Feb 1, 2020·Oncoimmunology·Patrycja CzerwinskaAndrzej Mackiewicz
Nov 30, 2018·Journal for Immunotherapy of Cancer·Jacek MackiewiczAndrzej Mackiewicz
Nov 1, 2018·Oncoimmunology·Eliza Kwiatkowska-BorowczykAndrzej Mackiewicz
Dec 9, 2020·Antioxidants·Halina WasAlicja Jozkowicz
Jan 14, 2021·Cancers·Anna PrzybylaPaul V Lehmann